# A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis

> **NCT00644800** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 89 (actual)

## Conditions studied

- Schizophrenia
- Mania
- Delusional Disorder
- Acute Exacerbation of Psychosis

## Interventions

- **DRUG:** Ziprasidone

## Key facts

- **NCT ID:** NCT00644800
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2004-05
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00644800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00644800, "A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT00644800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*